Australia markets close in 11 minutes

TOT BIOPHARM International Company Limited (1875.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
2.510-0.070 (-2.71%)
As of 01:00PM HKT. Market open.
Currency in HKD

Valuation measures4

Market cap (intra-day) 1.87B
Enterprise value 1.86B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.23
Price/book (mrq)2.53
Enterprise value/revenue 2.22
Enterprise value/EBITDA 165.84

Trading information

Stock price history

Beta (5Y monthly) 0.22
52-week change 318.35%
S&P500 52-week change 325.87%
52-week high 33.400
52-week low 30.800
50-day moving average 31.948
200-day moving average 31.842

Share statistics

Avg vol (3-month) 343.5k
Avg vol (10-day) 381.48k
Shares outstanding 5725.2M
Implied shares outstanding 6778.6M
Float 8172.23M
% held by insiders 142.98%
% held by institutions 128.40%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -4.84%
Operating margin (ttm)-1.43%

Management effectiveness

Return on assets (ttm)-0.98%
Return on equity (ttm)-5.39%

Income statement

Revenue (ttm)780.63M
Revenue per share (ttm)1.08
Quarterly revenue growth (yoy)74.00%
Gross profit (ttm)N/A
EBITDA 17.76M
Net income avi to common (ttm)-37.76M
Diluted EPS (ttm)-0.050
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)358.36M
Total cash per share (mrq)0.46
Total debt (mrq)345.65M
Total debt/equity (mrq)50.34%
Current ratio (mrq)1.81
Book value per share (mrq)0.89

Cash flow statement

Operating cash flow (ttm)56.43M
Levered free cash flow (ttm)-143.74M